<?xml version="1.0" encoding="UTF-8"?>
<ref id="B100-pharmaceuticals-12-00157">
 <label>100.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Oguntade</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ramharack</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Soliman</surname>
    <given-names>M.E.S.</given-names>
   </name>
  </person-group>
  <article-title>Characterizing the ligand-binding landscape of Zika NS3 helicase-promising lead compounds as potential inhibitors</article-title>
  <source>Future Virol.</source>
  <year>2017</year>
  <volume>12</volume>
  <fpage>261</fpage>
  <lpage>273</lpage>
  <pub-id pub-id-type="doi">10.2217/fvl-2017-0014</pub-id>
 </element-citation>
</ref>
